Eli Lilly schedules October 29 earnings as Eli Lilly stock sits 4.73 percent below its high

Published on 10/14/2026 at 15:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 22.97 billion in the second quarter. Eli Lilly stock costs EUR 1,054.60 on October 14, 2026, up 0.67 percent versus Xetra's October 13 close.

Reporting date and revenue growth

Eli Lilly has scheduled its third-quarter earnings call for October 29, 2026.
Revenue reached USD 22.97 billion in the second quarter of 2026, up 47.70 percent year over year.
Eli Lilly stock costs EUR 1,054.60 at Lang & Schwarz on October 14, 2026 at 3:09 p.m. CEST, up 0.67 percent versus the Xetra close of October 13, 2026 and 4.73 percent below the 52-week high.
The stock trades at a price-to-earnings ratio of 39.14 and has a market capitalization of EUR 991.8 billion.

Editorialfoto eines modernen Börsenhandelsraums mit grün leuchtenden Halbleiter-Kursanzeigetafeln und Händlern in Bewegung — Lam Research US5324571083 NASDAQ Boersenparkett Haendler vor grünen Halbleiter Kursanzeigetafeln Editorial Fotografie, Illustration mit AI erstellt.

Eli Lilly and Co. (US5324571083) has scheduled its third-quarter earnings call for October 29, 2026, according to the Eli Lilly investor-relations page. Eli Lilly stock sits 4.73 percent below its 52-week high of EUR 1,107.00, while the euro quote was EUR 1,054.60 at Lang & Schwarz on October 14, 2026 at 3:09 p.m. CEST, up 0.67 percent versus the Xetra close of October 13, 2026.

Revenue reached USD 22.97 billion

MarketBeat reported that revenue reached USD 22.97 billion in the second quarter of 2026, up 47.70 percent from the same quarter a year earlier. Earnings per share came to USD 8.38, compared with a USD 6.40 consensus estimate, a USD 1.98 difference.

The revenue comparison gives the October 29 reporting date more weight than the price move alone. For investors, the key question is whether Lilly can sustain this growth while the valuation remains elevated.

Stock sits below yearly high

The stock's 52-week range on the euro listing runs from EUR 662.90 to EUR 1,107.00. The current price is EUR 391.70 above the low and EUR 52.40 below the high, placing it closer to the top of the range.

The Lang & Schwarz quote showed a bid of EUR 1,052.80 and an ask of EUR 1,056.40 on October 14, 2026 at 3:09 p.m. CEST. The spread was EUR 3.60, while the Xetra comparison uses the October 13 close of EUR 1,047.60.

Valuation and next report

Eli Lilly's market capitalization was EUR 991.8 billion as of October 14, 2026, with a price-to-earnings ratio of 39.14 and a dividend yield of 0.01 percent. The valuation leaves the next earnings release as the clearest scheduled date for a fresh comparison with expectations.

The company operates in pharmaceuticals, with medicines spanning diabetes, obesity, cancer, immunology and neurological diseases. Its primary listing is on the New York Stock Exchange under ticker LLY, while this report uses the euro quotation for German investors.

Comparison with peers

Eli Lilly: plus 0.67 percent, P/E 39.14, market capitalization EUR 991.8 billion
AbbVie (NYSE, USD): minus 2.42 percent, P/E 77.29, market capitalization USD 484.6 billion
Merck & Co. (NYSE, USD): minus 2.39 percent, P/E 113.58, market capitalization USD 350.7 billion

Price and investor frame

Eli Lilly stock was trading at EUR 1,054.60 at Lang & Schwarz on October 14, 2026 at 3:09 p.m. CEST, up 0.67 percent versus the Xetra close of October 13, 2026 at EUR 1,047.60. The stock remained 4.73 percent below its 52-week high of EUR 1,107.00.

The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.